SCHEMBL22950481

SCHEMBL22950481

CNC(=O)c1cc2c(Oc3ncc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3Cl)ccnc2cc1OCC(C)=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 19/20 0.72
MERTK Q12866 10/20 0.72
MET P08581 7/20 0.67
AURKA O14965 1/20 0.59
RIPK2 O43353 1/20 0.59
ABCB11 O95342 1/20 0.59
ABL1 P00519 1/20 0.59
EGFR P00533 1/20 0.59
ERBB2 P04626 1/20 0.59
NTRK1 P04629 1/20 0.59
LCK P06239 1/20 0.59
PGR P06401 1/20 0.59
LYN P07948 1/20 0.59
RET P07949 1/20 0.59
CHRM2 P08172 1/20 0.59
HCK P08631 1/20 0.59
ADRA2A P08913 1/20 0.59
ADORA3 P0DMS8 1/20 0.59
KIT P10721 1/20 0.59
CHRM1 P11229 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22949464 0.92 AXL (0.85) AXLMERTKMETAURKARIPK2
SCHEMBL21208033 0.91 AXL (0.72) AXLMERTKMETAURKARIPK2
SCHEMBL22949581 0.90 AXL (0.70) AXLMERTKMETAURKARIPK2
SCHEMBL21208032 0.87 AXL (0.65) AXLMERTKMETAURKARIPK2
SCHEMBL29693398 0.85 AXL (0.87) AXLMERTKMETAURKARIPK2
SCHEMBL371819 0.85 AXL (0.87) AXLMERTKMETAURKARIPK2
SCHEMBL22949602 0.85 AXL (0.81) AXLMERTKMETAURKARIPK2
SCHEMBL22949533 0.84 AXL (0.81) AXLMERTKMETAURKARIPK2
SCHEMBL28537210 0.84 AXL (0.66) AXLMERTKMETAURKARIPK2
SCHEMBL21200866 0.84 AXL (0.85) AXLMERTKMETAURKARIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673897-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2023-06-13 US disclosed
US-11673897-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2023-06-13 US disclosed
US-20210032263-A1 Compounds for the Treatment of Kinase-Dependent Disorders EXELIXIS, INC. 2021-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210032263-A1 Compounds for the Treatment of Kinase-Dependent Disorders ERBB2, MAP3K6, PRKCH AXL 288/4885MERTK 22/4885MET 117/4885
US-11673897-B2 Compounds for the treatment of kinase-dependent disorders ERBB2, MAP3K6, PRKCH AXL 288/4885MERTK 22/4885MET 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.